Connection

Cristina Gervasoni to Drug Interactions

This is a "connection" page, showing publications Cristina Gervasoni has written about Drug Interactions.
Connection Strength

2.058
  1. Risks of potential drug-drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience. J Endocrinol Invest. 2021 Dec; 44(12):2849-2851.
    View in: PubMed
    Score: 0.520
  2. How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life? J Antimicrob Chemother. 2018 08 01; 73(8):2271-2273.
    View in: PubMed
    Score: 0.428
  3. Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. Drugs Aging. 2021 04; 38(4):341-346.
    View in: PubMed
    Score: 0.128
  4. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs Aging. 2020 12; 37(12):925-933.
    View in: PubMed
    Score: 0.125
  5. Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. Eur J Drug Metab Pharmacokinet. 2019 Jun; 44(3):319-327.
    View in: PubMed
    Score: 0.113
  6. Different effects of glucocorticoids on darunavir plasma concentrations. Eur J Clin Pharmacol. 2019 May; 75(5):733-735.
    View in: PubMed
    Score: 0.110
  7. Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic AIDS Rev. 2019; 21(1):40-49.
    View in: PubMed
    Score: 0.110
  8. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
    View in: PubMed
    Score: 0.103
  9. The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. Antivir Ther. 2018; 23(5):467-469.
    View in: PubMed
    Score: 0.103
  10. How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life? J Acquir Immune Defic Syndr. 2017 05 01; 75(1):e24-e26.
    View in: PubMed
    Score: 0.098
  11. Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. AIDS. 2017 03 27; 31(6):867-868.
    View in: PubMed
    Score: 0.097
  12. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
    View in: PubMed
    Score: 0.096
  13. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):193-201.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.